HCTPF
Hutchison Port Holdings Trust$0.2200 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $0.2200
1 year
+10.0%
from $0.2000 · Oct 27
30 days
0.0%
from $0.2200
52-week range
$0.1600–0.2200
0% from high · low Mar 6
Avg volume 20D
0
Sep 29 spike 0
Short interest
🔒 Subscribers only
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 12 Trial readout: Results Pending: Savolitinib (Phase 2) — Completed 21d ago
- E Jun 1 Trial readout: T-90d Trial Readout: Savolitinib (Phase 3)
- E Jun 12 Trial readout: Results Pending: Savolitinib (Phase 2) — Completed 52d ago
- E Jul 6 Trial readout: Results Pending: Savolitinib (Phase 2) — Completed 76d ago
- E Jul 17 Trial readout: Results Pending: Savolitinib (Phase 2) — Completed 87d ago
- X Sep 15 Short interest falls 67.2% to 223.5K
- X Sep 30 Short interest jumps 448.3% to 1.23M
Signal stack
Where each data set points today.
- TrendRANGE
2% above its 50-day average. New closing high $0.2200 on Oct 26.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 17, 2026 Clinical trial readout
Results Pending: Savolitinib (Phase 2) — Completed 87d ago
Trial: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 17, 2026
Trial readout
Results Pending: Savolitinib (Phase 2) — Completed 87d ago
Trial: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients Sponsor: Hutchison Medipharma Limited Phase…
Jul 6, 2026
Trial readout
Results Pending: Savolitinib (Phase 2) — Completed 76d ago
Trial: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients Sponsor: Hutchison Medipharma Limited Phase…
Jun 11, 2026
Trial readout
Results Pending: Savolitinib (Phase 2) — Completed 52d ago
Trial: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients Sponsor: Hutchison Medipharma Limited Phase…
May 31, 2026
Trial readout
T-90d Trial Readout: Savolitinib (Phase 3)
Trial: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Sponsor: Hutchison Medipharma…
May 27, 2026
Clinical Trial
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Phase 3 · COMPLETED
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $3.1B |
| Next Q | — | — | — | $3.1B |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short